Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.
Department of Medicine, Reading Health System, West Reading, PA, USA.
Naba R
NR
Mainali
Division of Hematology and Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Vijaya R
VR
Bhatt
Department of Medicine, Staten Island University Hospital, Staten Island, NY, USA.
Shiksha
S
Kedia
Division of Hematology and Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Jairam
J
Krishnamurthy
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Laura M
LM
Wake
Division of Hematology and Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA mojtaba.akhtari@unmc.edu.
Mojtaba
M
Akhtari
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D001853:Bone Marrow / Q000187:drug effects* / Q000473:pathology; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000175:diagnosis; D001856:Bone Marrow Examination; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a
Bone marrow aplasia; immunosuppression; myelosuppression; pancytopenia; pegylated interferon-α-2a; primary myelofibrosis